Literature DB >> 2992780

Immune reactivity to Thomsen-Friedenreich antigen in patients with lung cancer detected by superoxide assay-leukocyte adherence inhibition test.

Y Ichinose, K Yagawa, M Kaku, N Hara, M Ohta.   

Abstract

The immune reactivity to partially purified Thomsen-Friedenreich antigen was investigated in patients with lung cancer. The modified method of original leukocyte adherence inhibition test, termed superoxide assay-leukocyte adherence inhibition test, was used to detect the reactivity. The coded peripheral mononuclear cells from 34 of 50 (68%) patients with lung cancer showed a positive response to the antigen whereas in only 3 of 19 (16%) patients with benign pulmonary disease was there a reaction to the antigen. The same experiments were performed using the 3 m KCl extract of lung tumors as an antigen. In this case in 39 of 50 (78%) patients with lung cancer but in only 4 of 24 (17%) with benign pulmonary disease and in none of the breast cancer patients (0 of 17) was there a reaction to the antigen. These results strongly suggest that patients with lung cancer are sensitized to both Thomsen-Friedenreich antigen and tumor-associated antigens expressed in cancer cells of lung tissue origin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2992780

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Measurement by leukocyte adherence inhibition of autosensitization of cancer patients to myelin basic protein.

Authors:  Z Gouda; D M Thomson
Journal:  Jpn J Cancer Res       Date:  1988-04

2.  Prospective virome analyses in young children at increased genetic risk for type 1 diabetes.

Authors:  Kendra Vehik; Kristian F Lynch; Matthew C Wong; Xiangjun Tian; Matthew C Ross; Richard A Gibbs; Nadim J Ajami; Joseph F Petrosino; Marian Rewers; Jorma Toppari; Anette G Ziegler; Jin-Xiong She; Ake Lernmark; Beena Akolkar; William A Hagopian; Desmond A Schatz; Jeffrey P Krischer; Heikki Hyöty; Richard E Lloyd
Journal:  Nat Med       Date:  2019-12-02       Impact factor: 87.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.